Basic Tacrolimus Information

• INN (International Nonproprietary Name): Tacrolimus
• Brand Names Available In United Kingdom: Prograf®, Advagraf®, Protopic®; generics supplied by Sandoz, Mylan and Accord Healthcare; other international names include Tacni®, PanGraf® and Tacrolimus-Sandoz.
• ATC Code: L04AD02 (systemic calcineurin inhibitor); D11AH01 (topical dermatological)
• Forms & Dosages: Capsules 0.5mg, 1mg, 5mg; Extended‑release capsules 0.5mg, 1mg, 3mg, 5mg; IV 5mg/ml vials; Ointment 0.03% and 0.1% in 10g/30g/60g tubes; cream formulations occasionally compounded to 0.1%.
• Manufacturers In United Kingdom: Astellas Pharma (Prograf®, Protopic®, Advagraf®) and European generics manufacturers such as Sandoz, Mylan and Accord Healthcare.
• Registration Status In United Kingdom: Not specified in the source data; product licences are held regionally (EMA/other regulators) and tacrolimus is generally a prescription‑only medicine in the EU/UK market.
• OTC / Rx Classification: Prescription Only Medicine (Rx Only / POM)

Critical Warnings & Restrictions

High-Risk Groups (Elderly, Pregnancy, Chronic Illness)

Who should be treated with caution?

• Transplant recipients on lifelong immunosuppression — require close therapeutic drug monitoring (TDM).
• Elderly patients — start cautiously and monitor for nephrotoxicity, hypertension and drug interactions.
• People with hepatic or renal impairment — dose reduction and more frequent blood level checks advised.
• Pregnant or breastfeeding women — use only if benefits outweigh risks; specialist advice required.
• Patients with uncontrolled infections — avoid starting systemic tacrolimus until infection is controlled.
• Children — often need higher mg/kg doses and closer monitoring due to variable absorption.

Action points for UK prescribers and pharmacists include ensuring regular TDM for systemic use, following the product SmPC and reporting adverse events via the MHRA Yellow Card scheme.

Interaction With Activities (Driving, Workplace Safety Under UK Law)

Tacrolimus can cause tremor, dizziness and changes in vision in some people.

If these side effects occur avoid driving, operating heavy machinery or performing safety‑critical work until symptoms resolve.

Occupational health advice should be sought where job duties could pose risk to the patient or others.

Concomitant nephrotoxic medicines such as aminoglycosides and frequent NSAID use increase renal risk and should be reviewed before and during treatment.

Q&A — “Can I Drive After Taking It In The UK?”

Only if you are not experiencing side effects that impair driving, such as dizziness, tremor, blurred vision or severe fatigue.

If you notice any of these symptoms after taking tacrolimus do not drive and seek medical advice.

Contact your GP, transplant clinic or community pharmacist for specific guidance about when it is safe to resume driving.

Under UK guidance you should notify the DVLA if a medical condition or medication affects your ability to drive; the DVLA or your clinician can advise on legal obligations.

People performing safety‑critical work or operating heavy machinery should consult occupational health and their employer before returning to duties.

Keep a medicines record card that lists tacrolimus and carry it when travelling in case of an emergency.

If you are uncertain, err on the side of caution and arrange alternative transport until a clinician confirms it is safe.

For transplant patients, follow clinic advice precisely and report new neurological or visual symptoms immediately.

Seek help promptly.

Usage Basics

INN, Brand Names Available In The United Kingdom

Tacrolimus is the International Nonproprietary Name (INN) for this calcineurin inhibitor.

Common branded products encountered in UK practice include Prograf® (immediate‑release capsules and IV), Advagraf® (prolonged‑release capsules) and Protopic® (topical ointment).

Generics supplied by Sandoz, Mylan and Accord Healthcare are also commonly available.

Legal Classification (POM, P, GSL)

Both systemic and topical tacrolimus are prescription‑only medicines (POM) in the UK market.

Supply must follow a valid prescription and local NHS or hospital formulary arrangements for systemic agents, especially for transplant patients who require coordinated TDM and clinic follow‑up.

Packaging commonly uses foil blisters for capsules, glass ampoules for IV and aluminium tubes for ointment.

At point of dispensing a short counselling checklist is helpful: confirm patient identity, confirm indication, review dosing schedule, explain common side effects, and stress the need for blood monitoring for systemic use.

Dosing Guide

Standard Regimens (NHS Guidelines)

Systemic dosing is indication specific and requires specialist oversight for transplant patients.

Typical starting oral doses for renal and hepatic transplant recipients are around 0.1–0.2 mg/kg/day divided every 12 hours, adjusted to trough levels.

Cardiac transplant regimens may start near 0.075 mg/kg/day divided every 12 hours.

Extended‑release options such as Advagraf® are available in a range of strengths and are dosed once daily according to clinic guidance.

Topical tacrolimus (Protopic®) is applied as a thin layer twice daily; 0.03% is generally preferred in children under 16 and 0.1% in adults where tolerated.

Adjustments For Comorbidities

Children frequently require higher mg/kg doses and closer monitoring due to variable absorption.

Elderly patients and those with renal or hepatic impairment should have lower starting doses and more frequent TDM.

• Adjustment triggers: renal impairment, hepatic impairment, interacting drugs (CYP3A4/5 modulators), unexpectedly high trough blood levels.

Q&A — “What If I Miss A Dose?”

If within 4–6 hours of your usual dose, take the missed tacrolimus as soon as you remember.

If more than 4–6 hours have passed, skip the missed dose and continue the normal schedule; do not double the next dose.

Contact your transplant clinic or GP promptly if you have missed more than one dose or if you are unsure how many doses were missed.

For topical tacrolimus, if a single application is missed apply at the next scheduled time and avoid applying extra ointment to make up for the missed dose.

Multiple missed systemic doses in a transplant patient can raise the risk of rejection and require urgent clinical review and possibly blood level checks.

In the event of overdose seek immediate medical attention — there is no specific antidote.

Treatment focuses on supportive care and monitoring for nephrotoxicity and neurotoxicity.

If you have ongoing concerns call NHS 111 or go to A&E for symptoms such as severe tremor, seizures or reduced urine output.

Interaction Chart

Food And Drinks (Alcohol, Tea/Coffee, Diet Habits)

Tacrolimus is metabolised by CYP3A4/5 and is sensitive to food and drink influences that alter CYP activity or intestinal absorption.

Grapefruit and grapefruit juice can raise tacrolimus levels and should be avoided while taking the medicine.

Alcohol does not directly alter tacrolimus metabolism in the source data, but excessive alcohol use may worsen hepatic function and therefore affect drug handling.

Maintain consistent meal timing and composition where possible to reduce pharmacokinetic variability.

Common Drug Conflicts (MHRA Yellow Card Data)

Major drug interactions occur via CYP3A4/5 inhibition or induction and P‑glycoprotein modulation.

Report unexpected interactions or adverse events via the MHRA Yellow Card scheme.

User Reports & Trends

What patients commonly say on NHS Choices, Patient.info and parenting forums.

• Topical tacrolimus often causes a transient burning or tingling sensation when first applied.
• Many patients value topical tacrolimus as a steroid‑sparing option for sensitive areas.
• Systemic tacrolimus generates anxiety about infection risk and frequent blood testing among transplant patients.
• Confusion commonly arises between brand and generic names such as Prograf, Advagraf and tacrolimus generics.

Checklist of actions patients took: stop treatment temporarily, contact GP, seek pharmacist advice, or present to hospital for testing.

Clinicians should proactively explain common early topical reactions, the need for TDM for systemic use and clarify brand vs generic naming to reduce confusion.

Access & Purchase Options

Boots, LloydsPharmacy, Superdrug

Community pharmacy chains such as Boots and LloydsPharmacy and some large retail pharmacies dispense tacrolimus on a valid prescription.

Hospital pharmacies handle IV and systemic supplies for transplant patients, often as part of shared‑care arrangements.

Online Pharmacies And NHS E‑Prescriptions

Online pharmacies supply repeat prescriptions and home delivery where a valid prescription is provided; ensure the vendor is MHRA‑registered and GPhC‑regulated.

NHS Electronic Prescription Service (EPS) and hospital shared‑care arrangements are commonly used for routine dispensing and TDM coordination.

In our online pharmacy tacrolimus is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Pharmacy checklist to bring: prescription, hospital letter if relevant (transplant), current medication list and allergy history.

Mechanism & Pharmacology

Simplified Explanation

Tacrolimus is a calcineurin inhibitor that binds to the intracellular protein FKBP12 and blocks T‑cell activation.

For transplants this reduces the risk of graft rejection, and when applied topically it dampens inflammatory skin responses in atopic dermatitis.

Clinical Terms

Key terms to know:

• Calcineurin Inhibitor — blocks T‑cell signalling and cytokine production.
• TDM — therapeutic drug monitoring; blood trough levels guide dosing for systemic therapy.
• ATC Codes — L04AD02 for systemic tacrolimus; D11AH01 for topical formulations.

Systemic tacrolimus has highly variable absorption and is metabolised primarily by CYP3A4/5, explaining the need for TDM and attention to drug interactions.

Immediate‑release capsules and prolonged‑release formulations (Advagraf®) differ in dosing frequency and pharmacokinetic profiles.

A simple flowchart in patient leaflets helps explain how dosing, blood tests and symptoms link to safety.

Indications & Off‑Label Uses

MHRA‑Approved Uses

• Systemic tacrolimus: prevention of organ rejection in transplantation (renal, hepatic, cardiac).
• Topical tacrolimus (Protopic®): licensed for moderate‑to‑severe atopic dermatitis at 0.03% and 0.1% strengths.

Off‑Label Practices In NHS And Private Care

• Common off‑label dermatology uses: lichen planus, vitiligo and other inflammatory dermatoses under dermatology supervision.
• Off‑label use should be supported by documented rationale, informed consent and specialist follow‑up.

Topical preparations rarely cause systemic immunosuppression (<0.5%) but caution is needed with extensive application or when the skin barrier is broken.

Always consult the SmPC and local formularies before off‑label prescribing.

Key Clinical Findings

Summary of recent practice‑relevant findings from UK and EU cohorts and audits up to 2025.

Editors and authors should populate this table with direct citations from BMJ, Lancet or relevant transplant and dermatology journals when preparing final publication.

Clinician checklist: review TDM schedules, ensure infection prophylaxis where indicated, monitor blood pressure, glucose, lipids and electrolytes regularly.

Alternatives Matrix

NHS Prescribing Alternatives (Comparison Table)

Pros And Cons Checklist

• Consider ciclosporin when tacrolimus is contraindicated but discuss cosmetic and renal side effects.
• Use pimecrolimus for mild–moderate disease or steroid‑sparing in sensitive areas where topical absorption must be minimised.
• Discuss patient age, pregnancy plans, comorbid renal or hepatic disease and drug interaction potential before switching agents.

Suggested shared decision wording: “Given your kidney function, drug interactions and need for monitoring, these are the realistic benefits and risks of each option.”

Common Questions

• Can I breastfeed on tacrolimus? — Systemic tacrolimus passes into breast milk; breastfeeding may be possible only under specialist supervision and after discussion of risks and benefits with a transplant or maternal medicine team.
• Do I need extra vaccines? — Live vaccines are generally contraindicated for immunosuppressed patients; ensure inactivated vaccines are up to date and discuss influenza and pneumococcal vaccination with the team.
• How often are blood tests needed? — Early post‑transplant testing is intensive (days to weeks), then regular trough monitoring; frequency is increased with interacting drugs or altered renal/hepatic status.
• Is topical tacrolimus carcinogenic? — Current evidence and MHRA guidance do not show a clear causal link; use as directed, avoid unnecessary prolonged sun exposure and follow dermatology advice.

NHS Cost & Access Comparison Table

Checklist for patients seeking repeats: bring current prescription, hospital letter outlining regimen, recent TDM results and photo ID.

Registration & Regulation

MHRA Approval Process

Tacrolimus products are licensed regionally and are prescription‑only medicines.

Product licences and SmPCs are maintained by regulators such as the EMA and national agencies; suspected adverse reactions or defects should be reported through the MHRA Yellow Card scheme.

NHS Prescribing Framework

Prescribers must follow the SmPC and local NHS formulary guidance for tacrolimus use.

Systemic tacrolimus commonly requires a documented TDM schedule and shared‑care agreements between hospital specialists and primary care for ongoing prescribing and monitoring.

Storage & Handling

UK Household Storage (Cold/Damp Climate)

Capsules and ointments should be stored below 25°C in the original packaging and protected from moisture and light.

IV vials require refrigeration at 2–8°C and must not be frozen; follow immediate use instructions after dilution.

In UK homes avoid storing tacrolimus in bathrooms or near heat sources; choose a cool, dry cupboard away from sunlight.

Guidance From NHS And Pharmacists

• Keep medicines in original containers with labels intact.
• Use child‑safe storage and keep out of reach of children.
• Do not transfer tablets or ointments into unlabelled containers.

For travel carry medicines in original packaging with a copy of the prescription or hospital letter; refrigerate IV products in insulated cool bags if required and notify the pharmacy in advance for special handling.

Return unused or expired medicines to a pharmacy for safe disposal — do not flush or bin.

Guidelines For Proper Use

UK Pharmacist Counselling Style

Ask what the patient is being treated for and confirm the dosing schedule, whether immediate‑release or prolonged‑release formulations are supplied.

Explain the need for TDM in systemic use and the schedule for blood tests.

Review current medicines including OTC analgesics and supplements that can interact via CYP3A4/5 or increase nephrotoxic risk.

NHS Patient Safety Advice

• Explain urgent signs that require immediate review: fever, increased infections, reduced urine output, severe tremor or neurological changes.
• Advise avoidance of live vaccines when immunosuppressed and recommend a medicines card stating the patient is on tacrolimus.
• Provide Yellow Card reporting information and encourage patients to report unexpected side effects.

Pharmacist counselling checklist at supply: identity check, confirm pregnancy status, review allergies, give missed‑dose and overdose instructions and provide contact details for the transplant team or GP.

For clinicians include a brief audit checklist for reviewing adherence, side effects and TDM results at agreed intervals.

Delivery Across United Kingdom